DK0598818T3 - Escherichia coli O-polysaccharid-proteinkonjugatvaccine - Google Patents

Escherichia coli O-polysaccharid-proteinkonjugatvaccine

Info

Publication number
DK0598818T3
DK0598818T3 DK92918016T DK92918016T DK0598818T3 DK 0598818 T3 DK0598818 T3 DK 0598818T3 DK 92918016 T DK92918016 T DK 92918016T DK 92918016 T DK92918016 T DK 92918016T DK 0598818 T3 DK0598818 T3 DK 0598818T3
Authority
DK
Denmark
Prior art keywords
polysaccharide
present
coli
vaccines
escherichia coli
Prior art date
Application number
DK92918016T
Other languages
Danish (da)
English (en)
Inventor
Stanley J Cryz
Emil P Furer
Original Assignee
Stanley J Cryz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanley J Cryz filed Critical Stanley J Cryz
Application granted granted Critical
Publication of DK0598818T3 publication Critical patent/DK0598818T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK92918016T 1991-08-12 1992-08-11 Escherichia coli O-polysaccharid-proteinkonjugatvaccine DK0598818T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/743,787 US5370872A (en) 1991-08-12 1991-08-12 Escherichia coliO-polysaccharide-protein conjugate vaccine
PCT/US1992/006531 WO1993003765A1 (fr) 1991-08-12 1992-08-11 Vaccin a base de conjugues de polysaccharide-o d'escherichia coli et d'une proteine

Publications (1)

Publication Number Publication Date
DK0598818T3 true DK0598818T3 (da) 2001-03-19

Family

ID=24990179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92918016T DK0598818T3 (da) 1991-08-12 1992-08-11 Escherichia coli O-polysaccharid-proteinkonjugatvaccine

Country Status (12)

Country Link
US (1) US5370872A (fr)
EP (1) EP0598818B1 (fr)
JP (1) JP2763960B2 (fr)
AT (1) ATE198989T1 (fr)
AU (1) AU669854B2 (fr)
CA (1) CA2115564C (fr)
DE (1) DE69231673T2 (fr)
DK (1) DK0598818T3 (fr)
ES (1) ES2154263T3 (fr)
GR (1) GR3035662T3 (fr)
WO (1) WO1993003765A1 (fr)
ZA (1) ZA926063B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
EP0716613B1 (fr) * 1993-07-27 2003-07-09 Csl Limited Traitement de la maladie gastro-duodenale associee a une infection par helicobacter
US6872398B2 (en) * 1995-12-22 2005-03-29 The United States Of America As Represented By The Secretary Of The Army Conjugate vaccine against gram-negative bacterial infections
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
WO1998026799A1 (fr) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccin conjugue contre la salmonella paratyphi a
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2000070060A1 (fr) * 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production de glucides complexes
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
AU2001253568A1 (en) * 2000-04-18 2001-10-30 Dan C. Deborde Lipopolysaccharide-conjugate vaccine for sepsis treatment
EP1438387A4 (fr) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc Procedes de fabrication de glycomolecules a activite amelioree, et utilisations de ces dernieres
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
CA2703519C (fr) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Utilisation d'inhibiteurs de recepteurs tam en tant qu'immunostimulateurs et activateurs tam en tant qu'immunosuppresseurs
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
WO2012125553A2 (fr) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-glycanes contenant de la n-acétylhexosamine dans des produits de glycoprotéines
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
WO2014018747A2 (fr) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (fr) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
AU5675790A (en) * 1989-05-09 1990-11-29 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria

Also Published As

Publication number Publication date
ZA926063B (en) 1993-05-19
DE69231673D1 (de) 2001-03-08
US5370872A (en) 1994-12-06
DE69231673T2 (de) 2001-06-07
WO1993003765A1 (fr) 1993-03-04
CA2115564C (fr) 2002-01-22
JPH06510530A (ja) 1994-11-24
ATE198989T1 (de) 2001-02-15
JP2763960B2 (ja) 1998-06-11
AU2464192A (en) 1993-03-16
EP0598818A1 (fr) 1994-06-01
AU669854B2 (en) 1996-06-27
ES2154263T3 (es) 2001-04-01
EP0598818A4 (fr) 1995-04-05
CA2115564A1 (fr) 1993-03-04
EP0598818B1 (fr) 2001-01-31
GR3035662T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
GR3035662T3 (en) Escherichia coli o-polysaccharide-protein conjugate vaccine.
JP5759671B2 (ja) 結合方法
FI110164B (fi) Menetelmä oligosakkaridin valmistamiseksi depolymeroimalla antigeeninen polysakkaridi
KR100431236B1 (ko) 2,5-안히드로-d-만노오스터미널구조를갖는항원성b족연쇄구균타입ⅱ및타입ⅲ다당류및그의복합백신
CN105267974A (zh) 用于缀合疫苗的经过修饰的多糖
EA020459B1 (ru) Иммуногенная композиция
JP7439174B2 (ja) 免疫原性コンジュゲート及びその使用
EP0977588B1 (fr) Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides
BRPI0009163B8 (pt) composição imunogênica e vacina que a compreende
CA2297072A1 (fr) Conjugues immunogenes renfermant une porine meningococcique du groupe b et un polysaccharide h. influenzae
BR9507400A (pt) Composições imunogénicas de polissacaridio streptococal grupo a e processos
KR101044437B1 (ko) ５ 혈청형 폐렴연쇄구균 피막 폴리사카라이드의 환원적아민화에 의해 수득된 접합체
KR102428253B1 (ko) 신규한 다당류-단백질 접합체 및 이의 제조방법
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
KR970706845A (ko) 식물 또는 과실의 폴리사카라이드로부터 합성된 장티푸스 백신 및 그 제법(synthesis of typhoid fever vaccine from a plant or fruit polysaccharide)
CA2128212A1 (fr) Vaccin conjugue lps-toxine du cholera detoxifie pour la prevention du cholera
ES2686875T3 (es) Exopolisacárido de la bacteria Shigella sonnei, método para producirlo, vacuna y composición farmacéutica que lo contienen
Cryz et al. Escherichia coliopolysaccharide-protein conjugate vaccine
Arndt et al. Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae
Chennasamudram et al. CONJUGATE VACCINE PRODUCTION
CN118203657A (zh) 一种多糖结合疫苗及其制备方法和用途
MXPA98007617A (es) Conjugados de polisacaridos peptidos